SCHEMBL24070513

SCHEMBL24070513

Cc1nc(C(C)C)c(C(C)C)c(C(C)C)n1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31555357 0.87 KDM5B (0.31)
SCHEMBL17973799 0.79 GCGR (0.32)
SCHEMBL23370449 0.77
SCHEMBL25467513 0.75
SCHEMBL12316312 0.75 MEN1 (0.31)
SCHEMBL24832731 0.74
SCHEMBL10073170 0.73 KDM5B (0.34)
SCHEMBL12795977 0.72 GCGR (0.33)
SCHEMBL18999980 0.70
SCHEMBL12795957 0.70 KDM5B (0.31)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230203060-A1 FUSED TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) 2023-06-29 US disclosed
WO-2021239058-A1 FUSED TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF 劲方医药科技(上海)有限公司 2021-12-02 WO disclosed